Article
Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Thoracic cancer - 1 Jul 2026
Winardi Wira, Mitsuishi Yoichiro, Matsuda Hironari, Takahashi Fumiyuki, Hayakawa Daisuke, Kanamori Koichiro, Nakamura Ikuko, Wirawan Aditya, Hidayat Moulid, Wibowo Adityo, Shukuya Takehito, Tajima Ken, Hayashi Takuo, Kohsaka Shinji, Takahashi Kazuhisa
Abstract excerpt
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide. Although osimertinib is more effective than previous-generation drugs, its efficacy is often limited by both primary and acquired resistance. Cycling cancer persister cells (CPCs) have recently emerged as a transient, drug-tolerant subpopulation that may contribute to early resistance to targeted therapies. However, their biological...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.